An advisory panel to the FDA has recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.


In abstinence-motivated people with opioid dependence, symptoms of anxiety, depression or insomnia should not prevent switching from an opioid agonist to extended-release naltrexone (XR-NTX), researchers in Norway say.

Michael Thase, MD

Since Michael Thase, MD, became a psychiatrist in 1983, the landscape of depression treatments and approaches has changed dramatically.

Adults age 50 and older with vitamin D deficiency have a 75% increased risk of developing depression over the next 4 years, a longitudinal study suggests.

High-dose antipsychotic use in children and young adults without psychosis is associated with an increased risk of unexpected death, according to a study published online in JAMA Psychiatry.

The effectiveness of the vast majority of self-care interventions suggested for children and young people with anxiety and depression has not been evaluated, new research shows.



Approximately 750 of our fellow physicians, nurses, psychotherapists take their own lives each year, making it imperative that we begin to explore and understand the despair within our ranks.

In our world of ever-expanding pharmacologic options, we continue to see patients whose treatment may be compromised by non-adherence to our prescribed medication regimens.

Even 4 or 5 years ago, the future of depression treatment was coming toward us, but it was far enough off to look uncertain. Now, the future is almost here, close enough at least for us to begin getting a sense of what the general outlines will be.



Karen Anderson, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Hubert Fernandez, MD
Jyotsna Mehta, B.Pharm, MS; Xiaowu Sun, PhD; Asli Memisoglu, MS, ScD; Arielle Stanford, MD; Nikki Levy, BS; Mugdha Gore, B.Pharm, PhD
Alexandra Kuzman, DNP; Quiping Zhou, PhD; Jose Vazquez, MD
Carmela Benson, MS; Ahong Huang, MS; Li Wang, MA, PhD, MBA; Neeta Tandon, MA, PhD; Abigail Nash, PhD, MD; Onur Baser, MS, PhD
Donna Cox, PhD; Micha Levi, PhD; Laura Rabinovich, PhD; David Truong, PharmD, MS; David Stamler, MD



Psych Congress Steering Committee members Vladimir Maletic, MD, MS, and Jon W. Draud, MD, MS, discuss the clinical consequences of misdiagnosing mixed mood states.

Psych Congress Steering Committee members Vladimir Maletic, MD, MS, and Jon W. Draud, MD, MS, discuss established and emerging treatment options for patients with mixed mood states.

Dr. Murrough discusses new research regarding a novel approach for depression management.